reports
- Research Department
INFORME DIARIO 03 JULIO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: NATURGY. EUROPA: UNICREDIT. El Ibex recupera los 14.000 puntos Subidas en las bolsas de Europa a la espera de los datos de empleo hoy y mientras el euro volvía por debajo de 1,18 en su cruce Subidas en las bolsas de Europa a la espera de los datos de empleo hoy y mientras el euro volvía por debajo de 1,18 en su cruce frente al dólar. En los sectores del STOXX 600 mucha disparidad (10/20 en ganancias) lideradas por cíclicos como R. Básicos (fuertes ...
- Research Department
IBERIAN DAILY 03 JULY (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: NATURGY. IBEX back above 14,000 points European stock markets rallied, awaiting today’s employment data and with the euro returning below 1.18 against the dollar. The STOXX 600 sectors were a mixed bag (10/20 with gains), led by cyclicals like Basic Materials (sharp rise in copper due to early orders) and Autos, whereas Real Estate and Retail fell the most. On the macro side, in Spain June’s number of unemployed fell slightly less than expected, while Social Security registrations...
Sanofi: 1 director
A director at Sanofi bought 500 shares at 82.700EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire » Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier tri...
Press release: Availability of the Q2 2025 Aide mémoire
Press release: Availability of the Q2 2025 Aide mémoire Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on July 31, 2025. About Sanofi...
Press Release: Riliprubart granted orphan drug designation in Japan fo...
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living...
Communiqué de presse : Le riliprubart obtient la désignation de médica...
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme traitement potentiel meilleur de sa catégorieLa décision du ministère de la Santé, du Travail et des Affaires sociales du Japon s’ajoute aux désignations similaires aux États-Unis et en ...
- Stephane Foucaud
AUCTUS ON FRIDAY - 27/06/2025
AUCTUS PUBLICATIONS ________________________________________ New Zealand Energy (NZ CN)C: Financial update – New Zealand has received short term loans totalling C$0.48 mm from Charlestown Energy Partners and a company controlled by New Zealand’s Chairman. The loans, which were issued with an original issuance discount of 10%. are unsecured and non-convertible, with interest payable at 15% per annum and repayment is due on August 27, 2025, The company now intends to complete a private placement. ...
- Research Department
INFORME DIARIO 27 JUNIO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, OHLA, REDEIA, REPSOL. El mercado de divisas, nuevo foco de atención Jornada mixta en las bolsas europeas, que cotizaron divididas con la vista puesta en el dólar y el nuevo retroceso que sufrió ayer, cayendo a mínimos de 2022. En el STOXX 600 R. Básicos e Industriales fueron los sectores que más subieron, frente a las mayores caídas de Hogar y B. de Consumo (sectores con bastante exposición a dólar). Por el lado macro, en EE.UU. el PIB 1...
- Research Department
IBERIAN DAILY 27 JUNE (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IBERDROLA, OHLA, REDEIA, REPSOL. Spotlight now on the currency market It was a mixed session on European stock markets, which were a mixed bag with all eyes on the dollar and the drop it suffered yesterday, falling to a low since 2022. In the STOXX 600, Basic Materials and Industrials were the sectors rising the most, with Household Goods and Consumer Goods falling the most (sectors highly exposed to the USD). On the macro side, in the US the 1Q’25 GDP was lowered in its third rea...
- Virginia Romero
- Research Department
IBERIAN DAILY 26 JUNE (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, NATURGY. Stock markets consolidation Following Tuesday’s gains, European stock markets dropped in a session lacking macroeconomic data, with the NATO meeting and the agreement to reach 5.0% of spending in 2035 as the main drivers. In the STOXX 600, most sectors (14/20) saw corrections, led by Food and Media vs. the better performance of cyclical industries such as Automobiles and Technology. On the macro side, in Spain, the final 1Q’25 confirmed the preli...
- Research Department
INFORME DIARIO 26 JUNIO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, NATURGY. EUROPA: UNICREDIT. Consolidación de niveles Tras las ganancias del martes, las bolsas europeas cayeron en una jornada descargada de datos macro, y con la reunión de la OTAN y el acuerdo de llegar al 5,0% del gasto en 2035 como principal catalizador. En el STOXX 600 la mayoría de los sectores (14/20) cerraron con pérdidas, lideradas por Alimentación y Media frente al mejor comportamiento de los cíclicos Autos y Tecn...
Press Release: Riliprubart earns orphan drug designation in the US for...
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administ...
Communiqué de presse : Le riliprubart est désigné comme médicament orp...
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet actif induit par les anticorps chez les receveurs de transplantation du reinLe riliprubart a également été désigné comme médicament orphelin pour l’utilisation expérimen...
- Ahmed Ben Salem
- Jeremy Garnier
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
IDL ID LOGISTICS GROUP
KCO KLOECKNER & CO SE
SWP SWORD GROUP SE
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
ENI ENI S.P.A.
ISP INTESA SANPAOLO S.P.A.
REP REPSOL SA
ROS ROSENBAUER INTERNATIONAL AG
TUB TUBACEX S.A.
NDA AURUBIS AG
UCG UNICREDIT S.P.A.
AXS ACCSYS TECHNOLOGIES
TRE TECNICAS REUNIDAS SA
BP. BP P.L.C.
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
SHEL SHELL PLC
DSPW DOOSAN SKODA POWER A.S.
- Ahmed Ben Salem
- Jeremy Garnier
SGO COMPAGNIE DE SAINT-GOBAIN SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
IDL ID LOGISTICS GROUP
KCO KLOECKNER & CO SE
SWP SWORD GROUP SE
CDA COMPAGNIE DES ALPES SA
KER KERING SA
ENI ENI S.P.A.
ISP INTESA SANPAOLO S.P.A.
REP REPSOL SA
ROS ROSENBAUER INTERNATIONAL AG
TUB TUBACEX S.A.
UCG UNICREDIT S.P.A.
TRE TECNICAS REUNIDAS SA
BP. BP P.L.C.
PRX PROSUS N.V. CLASS N
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
SHEL SHELL PLC
DSPW DOOSAN SKODA POWER A.S.
- Ahmed Ben Salem
- Jeremy Garnier
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
IDL ID LOGISTICS GROUP
KCO KLOECKNER & CO SE
SWP SWORD GROUP SE
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
ENI ENI S.P.A.
ISP INTESA SANPAOLO S.P.A.
REP REPSOL SA
ROS ROSENBAUER INTERNATIONAL AG
TUB TUBACEX S.A.
NDA AURUBIS AG
UCG UNICREDIT S.P.A.
AXS ACCSYS TECHNOLOGIES
TRE TECNICAS REUNIDAS SA
BP. BP P.L.C.
CLA CLARANOVA SE
DSC1 DUTCH STAR C SHAR
OVH OVH GROUPE
SHEL SHELL PLC
DSPW DOOSAN SKODA POWER A.S.
- Ahmed Ben Salem
- Jeremy Garnier
SGO COMPAGNIE DE SAINT-GOBAIN SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
IDL ID LOGISTICS GROUP
KCO KLOECKNER & CO SE
SWP SWORD GROUP SE
CDA COMPAGNIE DES ALPES SA
KER KERING SA
ENI ENI S.P.A.
ISP INTESA SANPAOLO S.P.A.
REP REPSOL SA
ROS ROSENBAUER INTERNATIONAL AG
TUB TUBACEX S.A.
UCG UNICREDIT S.P.A.
TRE TECNICAS REUNIDAS SA
BP. BP P.L.C.
PRX PROSUS N.V. CLASS N
DSC1 DUTCH STAR C SHAR
CPR DAVIDE CAMPARI-MILANO N.V.
SHEL SHELL PLC
DSPW DOOSAN SKODA POWER A.S.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.